Navigation Links
PAR in Medical Technology

Spherix Reports First Quarter 2009 Earnings

...ockholders' equity Preferred stock, $0.01 par value, 2,000,000 shares authorized; ... - - Common stock, $0.005 par value, 50,000,000 shares authorized; ... 72,188 Paid-in capital in excess of par value 27,610,426 27,602,486 Treasury s...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

...d contingencies Shareholders' equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outs...ding - - Common stock $0.0001 par value, 190,000,000 shares authorized, 76,363,101 and 76,3...

Strativa Pharmaceuticals Provides Product Pipeline Update

... products division of a wholly owned subsidiary of par Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com . About par Pharmaceutical ...

Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball

...it is heartening to see that the procedure can be successful in allowing future professional athletes to the reach the highest level of competition on par with their peers," said Carolan. The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, res...

Pharmasset Reports Fiscal Year End 2008 Financial Results

...bilities 33,794,724 16,908,073 COMMITMENTS & CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,340,498 and 21,232,991 shares issued and outstanding at September 30,...

Alfacell Provides ONCONASE(R) NDA Submission Update

...iple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd....

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

...ckholders' Equity Preferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $.001 par value, 41,130,270 and 40,991,385 issued and outstanding as of Septe...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

...FS is an effective prophylactic FVIII replacement product has 'jump started' the standard of hemophilia care in the United States so that it is now on par with other developed countries, especially those in Western and Northern Europe." The FDA approval of Kogenate(R) FS for routine prophylaxis in chil...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

...45 16,908,073 -------------------------- COMMITMENTS STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,751,503 and 21,232,991 shares issued and outstanding at June 30, 2008 (unaudited) and September 30, 200...

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development

...uding the recently announced licensing of our thin film formulation of ondansetron, an anti-emetic therapy, to Strativa Pharmaceuticals, a division of par Pharmaceuticals. Our expectation is to partner our PharmFilm(R) escitalopram oxalate product with a pharmaceutical company that is competitively posit...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...ase visit http://www.strativapharma.com . About par Pharmaceutical par Pharmaceutical, Inc. develops, manufactures and ma...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...completed by the end of calendar year 2008. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...gredient at the site of infection. In July 2007, par Pharmaceutical, Inc. entered into an exclusive licensing agreement under which par received commercialization rights in the U.S. to B...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

...elopment for this target market. Therefore, the Company will direct its resources to concentrate on other drug programs. Immtech's licensing partners, par Pharmaceutical Companies, Inc. and BioAlliance Pharma SA, remain in full support of the Company. Immtech was informed in late December 2007 that a s...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

... 16,908,073 ------------------------------ COMMITMENTS STOCKHOLDER'S EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,288,614 and 21,232,991 shares issued and outstanding at December 31, 2007 and September 30, 2007, r...

Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference

... second-generation polymerase inhibitor, IDX184, delivered multi-log viral load reductions in HCV genotype-1 infected chimpanzees in just 4 days -- on par with the antiviral activity reported to date from protease inhibitors currently in development." Sommadossi continued, "In 2008, we look forward to ...

Immtech Reports Fiscal Second Quarter 2008 Results

...can sleeping sickness trial. During the three-month period ended September 30, 2007, several significant milestones were achieved. In addition to the par Pharmaceutical agreement, Immtech received orphan drug status from the USFDA for pafuramidine to treat malaria and African sleeping sickness, added a ...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...itments and contingencies Stockholders' equity: Preferred stock, $0.001 par value 5,000,000 shares authorized at September 30, 2007 and Decembe... 31, 2006 - - Common stock, $0.001 par value: Authorized shares, 75,000,000 at September 30, 2007 and D...

Chinese SFDA Grants Immtech Fast Track Status

...entered into an exclusive licensing agreement with par Pharmaceutical Companies, Inc. (NYSE: PRX ) under which par will receive commercialization rights in the U.S. ...lease visit http://www.immtechpharma.com . About par Pharmaceutical Companies, Inc. ...

Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

...estors purchased 23,605,551 Units ("Units") at a price of $1.08 per Unit with each Unit consisting of four shares of the Company's common stock, $0.01 par value, and a warrant to purchase one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issue...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

...e preferred stock - - Common stock 6,190 6,149 Capital in excess of par 329,237 327,228 Treasury stock (5,321) (5,321) Accumulated deficit ...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

...tablets. As previously announced, in November 2006 par entered into a supply and distribution agreement w...traZeneca's TOPROL-XL(R) extended release tablets. par began shipping 25 mg tablets of generic Toprol-XL ...king metoprolol succinate extended release. About par ...

DVT Awareness Survey Findings: Heart and Respiratory Patients

...s know only as much about it as the general population. * 52% of heart/respiratory patients have some knowledge about DVT -- on par with the general population (51%). * 40% of heart/respiratory patients have heard or read about DVT recently, the same percentage as...
Other Tags
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... for Bone and Mineral Research awarded Michael F. Holick, ... with the 2014 Louis V. Avioli Award. Holick, a ... internationally known for revolutionizing the understanding of vitamin D ... award honors a member of the American Society for ... bone and mineral basic research. It is named for ...
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
(Date:7/13/2014)... optical imaging device developed at Cedars-Sinai can provide ... the brain and are a classic sign of ... conducting a clinical trial in Australia. , The ... an oral presentation at the Alzheimer,s Association International ... invited by conference organizers to participate in a ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
(Date:7/13/2014)... ECS is being founded by Seattle ... a special needs child, I have become keenly aware ... contemporary special education resources and evidence-based instruction. Emerald City ... families in the Seattle metro area that are looking ... We welcome the opportunity to serve our community and ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According to ... this is a comprehensive program that teaches people how ... peripheral neuropathy without medications. This program also provides ... symptoms of peripheral neuropathy , including numbness, prickling, burning, ... its review that this home treatment program can help ...
(Date:7/12/2014)... According to the new market research ... Systems, and Naval Systems) - Global Forecasts and Analysis ... Surveillance Radar market are estimated to be $6.08 billion ... of 5.97% to reach $8.61 billion by 2020. , ... figures spread through 161 pages and in-depth TOC on ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4
Other Contents